Clinical Oncology
Laura Bush's partnership for breast cancer awareness in PanamaThe University of Texas M. D. Anderson Cancer Center marked the beginning of a collaborative effort to eradicate breast cancer in Panama through the Partnership for Breast Cancer Awareness and Research of the Americas today at an event with Laura Bush, the First Lady of the United States, and Vivian Fernández de Torrijos, the First Lady of Panama.
Colon cancer's genetic link to obesityA new study reveals the first-ever genetic link between obesity and colon cancer risk, a finding that could lead to greater accuracy in testing for the disease, said a researcher at the University of Alabama at Birmingham (UAB).
New therapy promising for melanoma skin cancerThe combination of two different biotherapies (interferon alfa-2b and tremelimumab) may be beneficial for patients with inoperable melanoma, revealed by researchers in US.
Breast cancer spread stopped by bone drugResearchers at Washington University School of Medicine in St. Louis found that women treated for stage II/III breast cancer who also received a bone strengthening drug zoledronic acid were less likely to have breast tumor cells growing in their bones after three months.
Novartis' Femara protects against breast cancer returnWomen may reduce the risk of their breast cancer returning by starting treatment with Femara (letrozole) anywhere from one to seven years after finishing tamoxifen therapy, according to a new analysis published in the Journal of Clinical Oncology.
Lower heart effects from Herceptin breast cancer treatment with chemotherapyA new pilot study by investigators at Memorial Sloan-Kettering Cancer Center (MSKCC) found that breast cancer patients can be treated safely with a "dose-dense" regimen of standard chemotherapy agents and the antibody trastuzumab (Herceptin), a drug that has previously been shown to cause cardiac toxicity.
Researchers identify protein that fuels ovarian cancerA protein that stimulates blood vessel growth worsens ovarian cancer, but its production can be stifled by a tiny bit of RNA wrapped in a fatty nanoparticle, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports in the Journal of the National Cancer Institute.
Anemia drugs for cancer patients raises blood clots riskTreating anemia with a class of drugs known as erythropoiesis-stimulating agents (ESAs) is associated with an increased risk of venous thromboembolism (blood clots in the deep veins of the legs or in the lungs) and death among patients with cancer, according to an article in the February 27 issue of JAMA.
Genentech's Avastin with chemotherapy approved for advanced breast cancerGenentech, Inc. (NYSE: DNA) announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval for Avastin (bevacizumab), in combination with paclitaxel chemotherapy, for the treatment of patients who have not received chemotherapy for their metastatic HER2-negative breast cancer.
$9 million grant for prostate cancer researchHenry Ford Hospital is embarking on an expanded major clinical trial involving the use of gene therapy in combination with radiation therapy, to determine if the combined treatment is more effective than radiation therapy alone for patients with intermediate risk prostate cancer.
RNA may stop breast cancer spreadNow, researchers can develop more effective drugs to prevent or treat cancer metastasis, as they have identified a specific group of microRNA molecules that are responsible for controlling genes that cause breast cancer metastasis.
Gleevec improves special leukemia in childrenGleevec, the targeted cancer pill that has saved more than 100,000 lives, now is saving more children with a dire leukemia, as well as preventing disease progression with long term use in adults with chronic myeloid leukemia.
Nexavar approved for patients with inoperable liver cancerThe U.S. Food and Drug Administration has approved Nexavar (sorafenib) for use in patients with a form of liver cancer known as hepatocellular carcinoma, when the cancer is inoperable. Nexavar was originally approved in 2005 for the treatment of patients with advanced renal cell carcinoma, a form of kidney cancer.